A-771726dihydroorotate dehydrogenase inhibitor |
Sample solution is provided at 25 µL, 10mM.
Quality Control & MSDS
- View current batch:
- Purity = 98.00%
- COA (Certificate Of Analysis)
- MSDS (Material Safety Data Sheet)
Chemical structure
A-771726 Dilution Calculator
calculate
A-771726 Molarity Calculator
calculate
Cas No. | 163451-81-8 | SDF | Download SDF |
Synonyms | Flucyamide,HMR 1726,SU 20,Teriflunomide | ||
Chemical Name | 2-cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2Z-butenamide | ||
Canonical SMILES | O=C(/C(C#N)=C(O)/C)NC1=CC=C(C(F)(F)F)C=C1 | ||
Formula | C12H9F3N2O2 | M.Wt | 270.2 |
Solubility | ≤10.7mg/ml in DMSO;21.6mg/ml in dimethyl formamide | Storage | Store at -20°C |
Physical Appearance | A crystalline solid | Shipping Condition | Evaluation sample solution : ship with blue ice.All other available size:ship with RT , or blue ice upon request |
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. |
A771726 is dihydroorotate dehydrogenase inhibitor.
The dihydroorotate dehydrogenase (DHODH) is a mitochondrial protein. Inhibitors of DHODH can be used to treat autoimmune diseases such as rheumatoid arthritis.
A771726, leflunomide"s active metabolite, showed significantly inhibitory effect on TNF-α and IL-1 at protein and transcription levels, and reduced production of IL-1 in monocultures of Kupffer cells (KCs) [1]. A-771726 reversibly inhibited dihydroorotate dehydrogenase, the rate-limiting step in the de novo synthesis of pyrimidines. A-771726 prevented activated lymphocytes from accumulating sufficient pyrimidines to support DNA synthesis with the IC50 values of 0.09, 3.5, and 12.5 μM for rat, mouse, and human, respectively [2]. A-771726 inhibited the activity of tyrosine kinases responsible for early T cell and B cell signaling in the G0/G1 phase of the cell cycle at higher doses [2]. A-771726 also inhibited the production of prostaglandin E2 in synoviocytes activated by TNF-α and IL-1α with the IC50 values of 7 and 3 μM, respectively. A771726 also inhibited MMP-1 and IL-6 production at concentrations >10 μM [3]. A771726 is a novel immunosuppressive compound that has been shown to be a powerful antiproliferative agent for mononuclear and T-cells. A771726 potently inhibited the activity of DHODase with the Ki of 179 ± 19 nM. A771726 was a competitive inhibitor of the ubiquinone binding site [4].
References:[1] Yao H W, Li J, Chen J Q, et al. A 771726, the active metabolite of leflunomide, inhibits TNF-α and IL-1 from Kupffer cells[J]. Inflammation, 2004, 28(2): 97-103.[2] Breedveld F C, Dayer J M. Leflunomide: mode of action in the treatment of rheumatoid arthritis[J]. Annals of the rheumatic diseases, 2000, 59(11): 841-849.[3] Burger D, Begué‐Pastor N, Benavent S, et al. The active metabolite of leflunomide, A77 1726, inhibits the production of prostaglandin E2, matrix metalloproteinase 1 and interleukin 6 in human fibroblast‐like synoviocytes[J]. Rheumatology, 2003, 42(1): 89-96.[4] Davis J P, Cain G A, Pitts W J, et al. The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase[J]. Biochemistry, 1996, 35(4): 1270-1273.